Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.
2018
4572Background: Although nivolumab, a programmed death 1 inhibitor, has been approved as a second line treatment for advanced renal-cell carcinoma (RCC) in Europe since 2016, its real-world experie...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI